Can dressings soaked with polyhexanide reduce bacterial loads in full-thickness skin grafting? A randomized controlled trial

Saleh, Karim; Sonesson, Andreas; Persson, Kerstin; Riesbeck, Kristian; Schmidtchen, Artur

Published in:
Journal of the American Academy of Dermatology

DOI:
10.1016/j.jaad.2016.07.020

2016

Document Version:
Peer reviewed version (aka post-print)

Can dressings soaked with polyhexanide reduce bacterial loads in full-thickness skin grafting? A randomized controlled trial.

Karim Saleh, MD[1*], Andreas Sonesson, MD, PhD[1], Kerstin Persson, BS[1], Kristian Riesbeck, MD, PhD[2], Artur Schmidtchen, MD, PhD[1,3]

[1]Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden

[2]Clinical Microbiology, Department of Translational Medicine, Lund University, Malmö, Sweden

[3]LKCMedicine, Nanyang Technological University, Singapore

[*]Correspondence: Division of Dermatology, Department of Clinical Sciences, Biomedical Center B14, Lund University, Tornavägen 10, SE-221 84 Lund, Sweden. Tel: +46 46 222 33 15. Fax: +46 46 15 77 56. Email: Karim.Saleh@med.lu.se

Word counts

Abstract: 240

Capsule summary: 65

Text: 2447

Number of references: 32

Tables: 1

Figures: 2

Supplementary tables and figures: 3

Ethical approval was granted by the ethical committee in Malmö/Lund, registration number (2013/762).

Registered at www.clinicaltrials.gov. **ClinicalTrials.gov Identifier:** NCT02253069

This article was funded by the program "Innovation mot infektion" (IMI), financed by the VINNOVA- Swedish governmental agency for innovation systems, the Swedish Government Funds for Clinical Research (ALF), and The Swedish Research Council (2012-1883).

Dr. Schmidtchen has received consulting support from Mölnlycke Health Care AB.

ABSTRACT

Background: Polyhexamethylene biguanide (PHMB)-based antiseptic solutions can reduce bacterial loads in different clinical settings and are believed to lower risk of infections.

Objective: To assess the efficacy of a PHMB-based solution in lowering bacterial loads of full-thickness skin grafting (FTSG) wounds and the risk of SSIs.

Methods: In this double-blinded clinical trial, 40 patients planned for facial FTSG were randomized 1:1 to receive tie-over dressings soaked with either PHMB-based solution or sterile water. Quantitative and qualitative bacterial analysis was performed on all wounds before surgery, at the end of surgery, and 7 days postoperatively. In addition, all patients were screened for nasal colonization of *S. aureus*.

Results: Analysis of wounds showed no statistically significant difference in bacterial reductions between the groups. The SSI rates were significantly higher in the intervention group (8/20) than in the control group (2/20) (P=.028). Higher postoperative bacterial loads were a common finding in SSIs (P=.011). This was more frequent when *S. aureus* was present postoperatively (P=.034), intraoperatively (P=.03), and in patients with intranasal *S. aureus* colonization (P=.007).

Limitations: Assessment of SSIs is largely subjective. In addition, this was a single-center study and the total number of participants was 40.

Conclusion: Soaking tie-over dressings with PHMB-solution in FTSG had no effect on postoperative bacterial loads and increased the risk of SSI development. The presence of *S. aureus* intranasally and in wounds preoperatively and postoperatively increased postoperative bacterial loads, which in turn resulted in significantly more SSIs.

Key words: Surgical site infections; dermatologic surgery; pathogenesis; prevention; wound infection; bacteria; *S. aureus*

Classifications:
212: Bacterial infections
790: Evidence-based medicine
1239: Infection
1660: Microbiology
2170: Prevention
2520: Surgery
2780: Wounds & wound healing

Capsule summary:

- PHMB as an antiseptic has gained popularity in different clinical settings but hasn't yet been studied in full-thickness skin grafting (FTSG).
- This trial showed that adding PHMB to tie-over dressings had no effect on reducing bacterial loads in wounds and resulted in more surgical site infections.
- Use of PHMB in FTSG as a method to prevent SSIs is questionable, and further clinical studies are warranted.

INTRODUCTION

Polyhexamethylene biguanide (PHMB) is a polymer used as a disinfectant and antiseptic. [1-6] In recent years, it has gained popularity and has been used safely in different clinical settings such as in intraoperative irrigation during nail surgery [1], treatment of burns [5], orthopedic surgery antisepsis [6], wound dressings [3], prevention of infections in peritoneal catheters [4], and in combination with negative-pressure wound therapy (NPWT) where it has been shown to be better than NPWT alone in treating infected wounds. [7]

The advantages of PHMB include broad antibacterial activity, good cell and tissue tolerability, low risk of contact sensitization, promotion of wound healing, and no development of bacterial resistance. [2] In addition to having an effect on Gram-negative bacteria [8], it also has effects against methicillin-resistant *Staphylococcus aureus* (MRSA). [9] The microbicidal effect of PHMB is comparable to that of chlorhexidine [10], but does not contain the toxic substituents found in chlorhexidine. [11]

In this study we investigated whether a PHMB-based antiseptic solution added to tie-over dressings used in full-thickness skin grafting (FTSG) could reduce bacterial load of wounds. This is a factor believed to have a role in the development of surgical site infections (SSIs) as previously published by our group. [12] We hypothesized that a reduction in the bacterial load would lower the risk of SSIs. We were also interested in examining the presence of *S. aureus* intranasally and wanted to study its relevance for SSIs. Recent studies have indicated that nasal colonization with *S. aureus* is an important risk factor for development of SSIs. [13-15] By analyzing bacterial quantities

148 and species at different stages of surgery, we sought to improve our understanding of
149 the development of SSIs and its complex pathogenesis.
150
151 ## METHODS
152 ### Study Design
153 We conducted this prospective, double-blinded, randomized, placebo-controlled trial
154 between September 2014 and September 2015 at Lund University Hospital, Sweden.
155 This single-center study was approved by the ethical committee in Malmö/Lund,
156 registration number (2013/762) and registered with ClinicalTrials.gov
157 (NCT02253069). All patients over age 18 planned for facial FTSG were allowed to
158 participate in the trial. We limited inclusion to surgery localized to the face because
159 bacterial loads are known to vary from one anatomical site to another. [16] All grafts
160 were harvested from the neck region. Exclusion criteria were diabetes, treatment with
161 antibiotics within the last four weeks prior to surgery, and planned antibiotic therapy.
162 Written informed consent was obtained from all patients before enrollment. The same
163 nurse prepared all patients for surgery, which included using a 0.5% chlorhexidine
164 solution for preoperative skin preparation. Four dermatologists performed surgery
165 under routine sterile conditions. One principal investigator was in charge of collecting
166 bacterial samples and assessing wounds postoperatively.
167
168 ### Power analysis and randomization
169 In a previous *in vitro* study, a reduction of >5 $\log_{10}$ was achieved with a concentration
170 of 0.02% PHMB against *S. aureus*. [10] We hypothesized that application of 0.1%
171 PHMB as found in the commercially available Prontosan® Wound irrigation solution
172 (B. Braun Medical, Switzerland) would at least reduce bacterial load in wounds by

173 half versus placebo. To get 80% power with an α-value of 0.05, it was calculated
174 that 16 patients were required in each group. By including 20 patients in each group
175 in this trial to allow for dropouts, noticeable differences in bacterial reduction would
176 be detected. Patients were randomized according to a list generated using QuickCalcs
177 (www.graphpad.com/quickcalcs).
178
179 ***In vitro* antibacterial assay**
180 Prior to this trial, *in vitro* experiments were performed to assess antibacterial activity
181 of PHMB. See Supplementary Methods.
182
183 **Intervention**
184 At the end of each surgery, once the skin graft had been sutured to the wound, a tie-
185 over dressing was cut from Mepilex®. It was then soaked with either Prontosan®
186 solution or sterile water (see Supplementary Methods for details) according to the
187 randomization protocol.
188
189 **Follow up**
190 All patients were planned for a single follow up 7 days after surgery. Skin grafts were
191 assessed in terms of redness, edema, discharge, graft take, and pain resulting in an
192 overall assessment by the blinded principal investigator classifying a wound as
193 "infected" or "non-infected". No scoring system was used for this purpose. Digital
194 photographs were taken of all wounds pre- and postoperatively.
195
196 **Bacterial load analysis**

Bacterial samples were blindly collected from each patient using Eswabs (Copan, Brescia, Italy). Swabs were taken in a controlled manner by swabbing in a circular motion for 10 seconds. This was done at 3 different phases. Before surgery (BS) prior to antisepsis, the skin area containing the suspected neoplasm planned for excision was swabbed to establish the starting bacterial load level. Next, at the end of surgery (ES), the skin graft sutured to the wound was swabbed to establish a second starting load level. A final swab was taken from the wound one week after surgery (1W) after removal of the tie-over dressing.

Each swab was analyzed quantitatively by counting CFU per cm^2 of area swabbed as well as the type of bacteria present. Bacterial quantification was done by serially diluting each swab to 3 different concentrations plating each concentrate onto a Todd-Hewitt agar plate using sterile glass beads and incubating all plates in 5% CO_2 at 37°C for 24 h. The CFU were then counted and were usually between 30 and 300 CFUs. The CFU was divided with the swab area to measure bacterial loads in CFU/cm^2. Bacterial species were determined via matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.

Intranasal swabs

Before surgery, an Eswab was rotated in the patient's naris that was closest to the neoplasm planned for excision. Typing was performed using MALDI-TOF to detect presence of *S. aureus*. No quantification was done on these swabs.

Statistics

Statistical analyses were performed with SPSS v.22 software (SPSS Inc., Chicago, IL). Bacterial load reduction was determined by using the following formulas:

CFU(1W)-CFU(BS), CFU(1W)-CFU(ES), CFU(1W)/CFU(BS), and CFU(1W)/CFU(ES). All median values obtained were compared using a Mann-Whitney U test to examine if differences existed between the groups. Differences in categorical variables were determined using the chi-square test. Differences in continuous variables were estimated using Student´s *t* test. Statistical significance was set at $P < .05$.

Outcome measures

Our primary measure was to compare bacterial load reductions in both groups. The development of SSIs was a secondary outcome in this trial, and the tertiary outcome was the intranasal presence of *S. aureus* and examining its relevance for the bacterial dynamics of surgical wounds.

RESULTS

Our *in vitro* trials showed that only dressings soaked with PHMB inhibited growth of both *S. aureus* and *S. epidermidis* (Supplementary Figure 1). This was in accordance with previously published studies demonstrating antibacterial properties of PHMB against various skin bacteria.[17-20] As for this trial, there were no significant differences in patient characteristics in each group in terms of age, sex, wound location, and tumor excised (Supplementary table 1). Most wounds were located on the nose, which is known to be the most common site of skin malignancies. [21] No significant differences were noted among the groups in bacterial load levels measured before surgery, at end of surgery, and after one week. (Supplementary Table 2). No significant differences were detected between the groups in terms of bacterial reduction via the four calculations described in Methods (Supplementary Table 2).

A total of 10 wounds were assessed as infected to give an overall SSI rate of 25% in this study. Eight of these wounds belonged to the intervention group, which had a statistically higher rate of infection (chi-square 4.8, *P*=.028). Statistical analyses showed that patient characteristics such as gender, age, and wound location did not correlate to SSI rates in this study. All patients with SSIs had a significantly higher bacterial load measured postoperatively after one week as illustrated in Figure 1A. When *S. aureus* was isolated from wounds postoperatively after one week, patients had a significantly higher bacterial load (Figure 1B). The presence of *S. aureus* intranasally before surgery was also associated with a higher postoperative bacterial load (Figure 1C). Whether coagulase-negative staphylococci (CoNS) were isolated from wounds postoperatively or not had no effect on postoperative bacterial loads, although a higher spread in the total CFUs was observed (Figure 2A). The presence of *S. aureus* at the end of surgery in patients resulted in significantly higher postoperative bacterial loads (Figure 2B).

Typing of all strains isolated from swabs revealed that CoNS and *S. aureus* were the predominant species (Table 1). The number of species successfully isolated from all patients was highest in in the swabs before surgery (27 different species) and lowest one week after surgery (8 species). Four out of 10 infected wounds contained *S. aureus*.

DISCUSSION

SSIs in dermatologic surgery result in unnecessary health costs as well as added pain, discomfort, and dissatisfactory cosmetic outcomes for patients. [22,23] Furthermore, the

use of preventative measures such as antibiotic prophylaxis, although sometimes warranted, can contribute to the emergence of resistant bacterial strains and give unwanted side effects, such as allergic reactions in patients. [24] Effective evidence-based measures are therefore highly needed—especially in FTSG surgery, which is normally associated with a higher rate of SSI. [25]

In this randomized controlled trial, we tested the efficacy of PHMB in preventing SSIs. Our results show that PHMB had no effect on reducing postoperative bacterial loads. Surprisingly, adding PHMB to tie-over dressings resulted in a significantly higher risk of SSI. Previous studies have shown that applying a certain antibacterial agent locally to wounds can suppress the growth of certain bacterial species, which can cause an overgrowth of other species that might be harmful. [26] Although speculative, it is possible that PHMB, by reducing the commensal flora, *i.e.* the microbiome, could give rise to an increased colonization of *S. aureus* or other pathogens. Indeed, there appeared to be a higher spread in the bacterial levels when *S. epidermidis* was absent postoperatively (Fig. 2A), and Gram-negative bacterial species were particularly detected in the PHMB-treated group one week after surgery (Table 1), findings suggestive of possible microbiome changes induced by PHMB. Clearly, the limited number of patients enrolled in this study makes it impossible to draw any firm conclusions on the protective role of commensals and the role of PHMB. However, it is worth noting that the microbiome has recently been attributed with important roles in protection against infections. For example, *Staphylococcus epidermidis* can produce antimicrobials, which can keep potential pathogens at bay. [27] *S. epidermidis* can also activate toll-like-receptor-2 (TLR2) signaling and induce

296 antimicrobial peptide expression, thus enabling the skin to mount an enhanced
297 response to pathogens. [28,29]
298
299 We found 27 different bacterial species before surgery making it impossible to
300 analyze which particular species could be responsible for increasing the risk of SSIs
301 from a statistical point of view. A quantification of each particular species would be
302 necessary to investigate this further. Here, only the total quantity of all bacteria in a
303 swab was measured. Nevertheless, it was interesting to note that the variation of
304 bacterial species was highest prior to surgery and lowest postoperatively in both
305 groups. Yet in 24 out of 40 patients, bacterial loads were higher postoperatively than
306 preoperatively. It appears that certain species exhibits a stronger tendency to grow
307 directly after surgery. Further studies in larger patient groups are needed to verify this
308 observation. Another result was that the bacterial species observed here agreed well
309 with previously published studies showing that most frequently isolated species from
310 wounds are *S. aureus* and CoNS. [30]
311
312 In this trial, we established two different starting bacterial loads due to the nature of
313 FTSG surgery where skin is moved from one anatomical site to another. Comparing
314 postoperative bacterial loads present on a graft to the presurgical swab taken on
315 anatomically different skin would be unfair. We therefore compared the postoperative
316 bacterial loads levels with the levels observed before and at end of surgery. Our
317 analyses showed that the PHMB-based dressing had no effect on reducing
318 postoperative bacterial loads. Indeed, there was actually a tendency towards higher
319 loads one week after surgery in the intervention group compared to the control group.
320 The extensive variety of bacterial species found preoperatively (27 different species)

is yet another interesting finding. We could only compare these data to the variety present postoperatively (8 different species). Thus, this difference could again be attributed to the anatomical skin flora variations *per se* at the donor sites or to the microbiome and host defense changes as mentioned above. Another theory in line with a recent publication [31] is that the presence of a neoplasm in the swab taken preoperatively is somehow related to a high bacterial variety.

We validated our previously published findings [12] and showed that a total postoperative bacterial load correlates positively to wound infection. Furthermore, postoperative bacterial loads were shown to be significantly higher when *S. aureus* was present in wounds intra- and postoperatively as well as in patients who had a nasal colonization with *S. aureus* detected prior to surgery. However, there was no direct relationship between presence of *S. aureus* in wounds, or intranasally, and SSIs. Still, *S. aureus* appears to continue to be one of the key pathogens involved in the development of SSIs. The presence of CoNS in wounds on the other hand seems to reduce the tendency towards developing an SSI by a reduced postoperative bacterial load. However, this observation was not statistically significant ($P=.08$) as shown in Figure 2a. Although speculative, it is thus possible that an expanded preoperative screening of bacteria present preoperatively—not only in the nares, but also at the surgical site—could aid in the prediction of SSIs. It is also possible that boosting of the "healthy" microbiome—including *S. epidermidis*—could be beneficial for wound healing outcomes and in ongoing *in vitro* based experiments. Thus, we therefore are currently evaluating the effects of both commensal and pathogenic bacteria in skin models.

A limitation of our study is that one of our outcomes (diagnosis of SSIs) was dependent on a subjective assessment of a single investigator. Studies have shown both inter- and intra-observer variations when diagnosing SSIs [32]. These show the importance of finding a more objective method of diagnosing SSIs in the future. Nevertheless, the SSI scoring was performed in a blinded fashion to avoid potential bias between the groups. Other limitations were that this was a single-center study and that the total number of participants in the study was 40.

CONCLUSION

We used PHMB as a novel disinfectant to prevent SSIs in FTSG. PHMB appeared to increase the risk of SSIs at least in the experimental setting used here. In light of the emergence of new resistant bacterial strains that cause SSIs, there is a need for further research that can define preventative methods to improve outcomes. Measures that lower bacterial loads, prevent *S. aureus* regrowth in wounds and abolish intranasal colonization are important and ongoing.

Acknowledgments

We are greatly indebted to Mina Davoudi, Emma Matsson, Ann-Charlotte Strömdahl, and Dr. Ingrid Siemund for their efforts in conducting the study. We also wish to thank the nursing staff (Eva Jacobsson, Helene Palmqvist, Susanne Erdmann) and Åse Jönsson at our clinic for valuable assistance making this trial possible.

Abbreviations used:

SSI: Surgical site infection

FTSG: Full-thickness skin grafting

PHMB: Polyhexamethylene biguanide

NPWT: Negative-pressure wound therapy

MRSA: Methicillin-resistant *Staphylococcus aureus*

CFU: Colony-forming-unit

MALDI-TOF: Matrix-assisted laser desorption/ionization time-of-flight

TLR2: Toll-like-receptor-2

CoNS: Coagulase-negative staphylococcus

1. Becerro de Bengoa Vallejo R, Losa Iglesias ME, Cervera LA, Fernandez DS, Prieto JP. Efficacy of intraoperative surgical irrigation with polihexanide and nitrofurazone in reducing bacterial load after nail removal surgery. J Am Acad Dermatol 2011;64:328-35.
2. Eberlein T, Assadian O. Clinical use of polihexanide on acute and chronic wounds for antisepsis and decontamination. Skin Pharmacol Physiol 2010;23 Suppl:45-51.
3. Eberlein T, Haemmerle G, Signer M, et al. Comparison of PHMB-containing dressing and silver dressings in patients with critically colonised or locally infected wounds. J Wound Care 2012;21:12, 4-6, 8-20.
4. Nunez-Moral M, Sanchez-Alvarez E, Gonzalez-Diaz I, et al. Exit-site infection of peritoneal catheter is reduced by the use of polyhexanide. results of a prospective randomized trial. Perit Dial Int 2014;34:271-7.
5. Piatkowski A, Drummer N, Andriessen A, Ulrich D, Pallua N. Randomized controlled single center study comparing a polyhexanide containing bio-cellulose dressing with silver sulfadiazine cream in partial-thickness dermal burns. Burns 2011;37:800-4.
6. Rohner E, Seeger JB, Hoff P, et al. Preferred use of polyhexanide in orthopedic surgery. Orthopedics 2011;34:e664-8.
7. Kim PJ, Attinger CE, Steinberg JS, et al. The impact of negative-pressure wound therapy with instillation compared with standard negative-pressure wound therapy: a retrospective, historical, cohort, controlled study. Plast Reconstr Surg 2014;133:709-16.
8. Fabry WH, Kock HJ, Vahlensieck W. Activity of the antiseptic polyhexanide against gram-negative bacteria. Microb Drug Resist 2014;20:138-43.
9. Rietkotter J, Korber A, Grabbe S, Dissemond J. Eradication of methicillin-resistant Staphylococcus aureus in a chronic wound by a new polyhexanide hydrogel. J Eur Acad Dermatol Venereol 2007;21:1416-7.
10. Muller G, Kramer A. Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. J Antimicrob Chemother 2008;61:1281-7.
11. Hubner NO, Matthes R, Koban I, et al. Efficacy of chlorhexidine, polihexanide and tissue-tolerable plasma against Pseudomonas aeruginosa biofilms grown on polystyrene and silicone materials. Skin Pharmacol Physiol 2010;23 Suppl:28-34.
12. Saleh K, Sonesson A, Persson B, Riesbeck K, Schmidtchen A. A descriptive study of bacterial load of full-thickness surgical wounds in dermatologic surgery. Dermatol Surg 2011;37:1014-22.
13. Cordova KB, Grenier N, Chang KH, Dufresne R, Jr. Preoperative methicillin-resistant Staphylococcus aureus screening in Mohs surgery appears to decrease postoperative infections. Dermatol Surg 2010;36:1537-40.
14. Tai YJ, Borchard KL, Gunson TH, Smith HR, Vinciullo C. Nasal carriage of Staphylococcus aureus in patients undergoing Mohs micrographic surgery is an important risk factor for postoperative surgical site infection: a prospective randomised study. Australas J Dermatol 2013;54:109-14.
15. Cherian P, Gunson T, Borchard K, et al. Oral antibiotics versus topical decolonization to prevent surgical site infection after mohs micrographic surgery--a randomized, controlled trial. Dermatol Surg 2013;39:1486-93.

16. Grice EA, Kong HH, Conlan S, et al. Topographical and temporal diversity of the human skin microbiome. Science 2009;324:1190-2.
17. Kirker KR, Fisher ST, James GA, McGhee D, Shah CB. Efficacy of Polyhexamethylene Biguanide-containing Antimicrobial Foam Dressing Against MRSA Relative to Standard Foam Dressing. Wounds 2009;21:229-33.
18. Minnich KE, Stolarick R, Wilkins RG, et al. The effect of a wound care solution containing polyhexanide and betaine on bacterial counts: results of an in vitro study. Ostomy Wound Manage 2012;58:32-6.
19. Kamaruzzaman NF, Firdessa R, Good L. Bactericidal effects of polyhexamethylene biguanide against intracellular Staphylococcus aureus EMRSA-15 and USA 300. J Antimicrob Chemother 2016;71:1252-9.
20. Rembe JD, Fromm-Dornieden C, Schafer N, Bohm JK, Stuermer EK. Comparing two polymeric biguanides: Chemical distinction, antiseptic efficacy and cytotoxicity of Polyaminopropyl biguanide (PAPB) and Polyhexamethylene biguanide (PHMB). J Med Microbiol 2016.
21. Janjua OS, Qureshi SM. Basal cell carcinoma of the head and neck region: an analysis of 171 cases. J Skin Cancer 2012;2012:943472.
22. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA 2003;290:1868-74.
23. Nestor MS. Prophylaxis for and treatment of uncomplicated skin and skin structure infections in laser and cosmetic surgery. J Drugs Dermatol 2005;4:s20-5.
24. Rossi AM, Mariwalla K. Prophylactic and empiric use of antibiotics in dermatologic surgery: a review of the literature and practical considerations. Dermatol Surg 2012;38:1898-921.
25. Dixon AJ, Dixon MP, Askew DA, Wilkinson D. Prospective study of wound infections in dermatologic surgery in the absence of prophylactic antibiotics. Dermatol Surg 2006;32:819-26; discussion 26-7.
26. Smack DP, Harrington AC, Dunn C, et al. Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. JAMA 1996;276:972-7.
27. Christensen GJ, Bruggemann H. Bacterial skin commensals and their role as host guardians. Benef Microbes 2014;5:201-15.
28. Lai Y, Cogen AL, Radek KA, et al. Activation of TLR2 by a small molecule produced by Staphylococcus epidermidis increases antimicrobial defense against bacterial skin infections. J Invest Dermatol 2010;130:2211-21.
29. Gallo RL, Nakatsuji T. Microbial symbiosis with the innate immune defense system of the skin. J Invest Dermatol 2011;131:1974-80.
30. Saleh K, Schmidtchen A. Surgical site infections in dermatologic surgery: etiology, pathogenesis, and current preventative measures. Dermatol Surg 2015;41:537-49.
31. Hoste E, Arwert EN, Lal R, et al. Innate sensing of microbial products promotes wound-induced skin cancer. Nat Commun 2015;6:5932.
32. Bruce J, Russell EM, Mollison J, Krukowski ZH. The quality of measurement of surgical wound infection as the basis for monitoring: a systematic review. J Hosp Infect 2001;49:99-108.



C



Figure 1. Postoperative bacterial loads after one week shown for each patient group (controls and PHMB) or all patients combined. (A) Differences between wounds classified as infected and non-infected. (B) Differences in regard to presence of *S. aureus* in wounds at one week after surgery. (C) Levels correlated to presence of *S. aureus* intranasally. Outliers in all plots are indicated by an asterisk (⋆). Solid bars depict interquartile range and the hash marks show the total range. A difference in median CFU/cm^2 (calculated using Mann-Whitney´s test) with a *P* value of <.05 is regarded as statistically significant.

A B



Figure 2. Bacterial loads at one week after surgery measured in all patients whether (A) CoNS were isolated postoperatively and whether (B) *S. aureus* was isolated at end of surgery. The outliers were expressed with an asterisk (⋆). Solid bars depict interquartile range and the hash marks show the total range. Calculations of median CFU/cm^2 values using a Mann-Whitney test with a *P* value of <.05 were regarded as statistically significant.



Table 1. Bacterial species isolated before surgery (BS), after one week (1W), and intranasally (Nasal). Each row represents a patient. An asterisk (*) in the beginning of each row indicates patients developing an SSI.

SUPPLEMENTARY DATA

METHODS

In vitro antibacterial assay

Todd-Hewitt (TH) agar plates were streaked with *S. aureus* ATCC 29213 and *S. epidermidis* ATCC 14909. Each plate contained $1x10^5$ colony-forming units (CFU). Eight mm polyurethane dressings (Mepilex®, Mölnlycke Healthcare, Göteborg, Sweden) soaked with Prontosan® solution or sterile water were applied on top to simulate an *in vivo* situation where the dressing is applied onto a wound. The dressings were soaked with 70% of the solution, where 100% was considered as the maximum wetting capacity of the dressing. 70% wetting was also to be used in this patient trial. The zone of inhibition around the discs was measured.

Preparation of Mepilex® dressings

Prior to surgery, seven circular dressing templates with varying diameters ranging from 10 mm to 34 mm were cut from Mepilex®. Necessary liquid volume to achieve 70% wetting was calculated by subtracting each template's fully saturated weight from its dry weight and multiplying the result by 0.7. For each dressing template, 20 test tubes were prepared containing sterile water and 20 test tubes contained Prontosan® solution. These were marked with either A or B by an external investigator not involved in this trial and blinded to the nurse, surgeon, and principal investigator. Prontosan® solution is like water both colorless and odor-free. The dressing templates were used for proper determination of the volume of Prontosan® or sterile water required for wetting tie-over dressings used during surgery.

603 **FIGURES**

604 A B

605



606
607
608

609 **Figure 1.** *In vitro* antibacterial assays illustrating measured inhibition zones of

610 dressings soaked with water (control) or PHMB on agar plates coated with

611 $1x10^5$ CFU of (A) *S. aureus*, and (B) *S. epidermidis* (n=3, bar indicates S

Item	Intervention group	Control group	*P value*
Age			.351
Range	47-92	45-91	
Mean ± SD	74.45 ± 12.05	78.20 ± 13.05	
Median	74	85	
Sex, n (%)			.204
Male	11	7	
Female	9	13	
Wound location			.216
Nose	13	10	
Cheek	1	5	
Temple	3	1	
Forehead	2	2	
Ear	0	2	
Scalp	1	0	
Tumor excised			.435
BCC	15	15	
SCC	3	1	
Other	2	4	

BCC: Basal cell carcinoma. SCC: Squamous cell carcinoma.

Table 1. Patient characteristics and selected baseline values.

	Intervention Group	Control Group	*P* value
Median BS (CFU/cm^2)	10640.50	12180.50	.752
Median ES (CFU/cm^2)	13	13	.751
Median 1W (CFU/cm^2)	64132.50	23425.50	.752
Change (ES-1W)	5668.15	779	.608
Change (BS-1W)	2.7	1.1	.150
Difference 1W minus ES	64105.50	23415.50	.752
Difference 1W minus BS	28903.50	204.50	.343

623

624 **Table 2.** Bacterial quantification of all swabs taken before surgery (BS), at
625 end of surgery (ES), and after one week (1W).